Scotland Extends Exclusive National Agreement for Cytyc's ThinPrep(R) Pap Test

The decision follows the successful national conversion fromconventional pap smears to the ThinPrep Pap Test in Scotland begun in2003. Since implementation of the ThinPrep(R) System, the ScottishCervical Screening Programme has noted a range of clinical benefitsrelated to the product, including a reduction in the number of patientrecalls due to unsatisfactory specimens and a steady reduction inturnaround time for reporting results. Each year more than 440,000women participate in the Scottish Cervical Screening Programme and 11laboratories are responsible for processing the tests.

"We are very proud to continue our partnership with the ScottishCervical Screening Programme to provide ThinPrep technology to allwomen in Scotland," said David P. Harding, senior vice president ofCytyc Corporation and president of Cytyc International. "It is alsoparticularly gratifying that the decision to extend the currentexclusive agreement was partly based on the clinical performance ofthe ThinPrep Pap Test."

"We have been very impressed with the clinical efficacy of theThinPrep technology as well as the robust sample identification andsimplified processing afforded by this technology," said Dr. JocelynImrie, consultant cytopathologist and quality assurance adviser forScotland.

Cytyc Corporation is a leading women's health company thatdesigns, develops, manufactures, and markets innovative and clinicallyeffective products. Cytyc products cover a range of women's healthapplications, including cervical cancer screening, breast cancer riskassessment, treatment of excessive menstrual bleeding, and treatmentof breast cancer.

Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC.Cytyc and ThinPrep are registered trademarks of Cytyc Corporation.

Forward-looking statements in this press release are made pursuantto the provisions of Section 21E of the Securities Exchange Act of1934. Investors are cautioned that statements in this press releasewhich are not strictly historical statements, including, withoutlimitation, statements relating to Cytyc's future financial condition,operating results and economic performance, and management'sexpectations regarding key customer relationships, future growthopportunities, product acceptance and business strategy, constituteforward-looking statements. These statements are based on currentexpectations, forecasts and assumptions that are subject to risks anduncertainties, which could cause actual outcomes and results to differmaterially from those statements. Risks and uncertainties include,among others, dependence on key personnel and customers as well asreliance on proprietary technology, uncertainty of product developmentefforts and product acceptance, management of growth and productdiversification, entry into new market segments domestically and newinternational markets, risks associated with litigation, the effectiveintegration of acquired businesses and technologies, competition andcompetitive pricing pressures, risks associated with the FDAregulatory approval processes and healthcare reimbursement policies inthe United States and abroad, introduction of technologies that aredisruptive to Cytyc's business and operations, the impact of newaccounting requirements and governmental rules and regulations, aswell as other risks detailed in Cytyc's filings with the Securitiesand Exchange Commission, including under the heading "Certain FactorsWhich May Affect Future Results" in its 2004 Annual Report on Form10-K and its most recent Quarterly Report on Form 10-Q filed with theCommission. Cytyc cautions readers not to place undue reliance on anysuch forward-looking statements, which speak only as of the date theywere made. Cytyc disclaims any obligation to publicly update or reviseany such statements to reflect any change in its expectations orevents, conditions, or circumstances on which any such statements maybe based, or that may affect the likelihood that actual results willdiffer from those set forth in the forward-looking statements.